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ERYTHROPOIETIN (Epo) is a major regulator of the red blood cell production, widely used in clinics to treat anemia (21, 47) . Along with its erythropoietic properties, Epo nowadays is considered as a pleiotropic cytoprotective factor (22, 28) . Binding of Epo to its receptor (EpoR) activates several survival signaling cascades, including phosphatidylinositol-3-kinase (PI3K)/Akt pathway in endothelial cells (4, 51) and cardiomyocytes (12) . In both cell types studied, Epo upregulates the expression of endothelial-type nitric oxide (NO) synthase (eNOS) and directly enhances the enzyme activity via PI3K/ Akt-mediated phosphorylation of serine-1177 (Ser-1177) (4, 12, 51) . Recent reports suggested that Epo-induced regulation of NO production has a pivotal role in the cytoprotective effects of Epo (12, 18, 29, 51) .
The presence of EpoR on erythrocyte membranes is disputable. The data found in the literature are controversial and the responses of mature red blood cells (RBCs) to Epo treatment are poorly investigated. The expression of EpoR during the late erythroid development decreases exponentially, and mature erythrocytes were claimed to virtually lack EpoR and to be Epo insensitive (9, 60) . However, specific binding of Epo to rat and human RBCs was reported (3, 45) . Epo was shown to have an effect on glucose transport (3, 23) , antioxidant defense systems (13, 15) , ion transport (5, 45) , and rheological properties (26, 58) of mature RBCs. At present, no data are available on the Epo-binding sites on erythrocyte membranes or their distribution within RBC population.
As a putative downstream target of Epo-induced signaling in RBCs, we have chosen eNOS (RBC-eNOS), which presence in human and mouse erythrocytes was recently reported (33) . The activity of the RBC-eNOS is comparable to that observed in conventional endothelium-derived eNOS (33) . It is shown that insulin activates RBC-eNOS by phosphorylation of the enzyme at Ser-1177 via the PI3K/Akt pathway (33) .
The aim of the present study was to characterize the binding of Epo to murine erythrocytes and the effect of physiological and therapeutic doses of Epo on RBC-eNOS. Our data indicate the presence of a single class Epo binding sites, similar in affinity and downstream targets to a classical EpoR. We have shown that Epo-binding sites are not equally distributed within RBC population. Reticulocytes and young erythrocytes contain more Epo binding sites when compared with adult and old cells. Epo treatment results in upregulation of erythrocyte NO production via activation of PI3K/Akt-signaling pathway and phosphorylation of RBC-eNOS at Ser-1177. Additionally, we provide evidences for a direct link between the Epo-induced regulation of RBC-eNOS activity and the maintenance of the redox state in mouse RBCs.
MATERIALS AND METHODS
All chemicals and kits used in this study were purchased from Sigma Aldrich, St. Louis, MO when not stated specifically.
Animals and RBC Preparation
In the present study we used male C57BL/6 mice (WT), 12 to 20 wk old, and homozygous eNOS-deficient mice (eNOS Ϫ/Ϫ ). The animals were raised in the sterile breeding facilities at the Institute of Veterinary Physiology, University of Zurich. The mice were kept on a commercial diet as approved by the Veterinary Department of Canton Zurich. All experiments were approved and performed in accordance with the Swiss animal protection laws and institutional guidelines. Animals were euthanized with CO 2, and blood was collected immediately by cardiac puncture (0.8 -1.2 ml) into heparinized syringes. The packed cells were washed three times in incubation medium (in mM: 150 NaCl, 5 KCl, 1 CaCl 2, 0.15 MgCl2, 10 Tris-MOPS, 10 glucose, and 10 sucrose, pH 7.4). Buffy coat and plasma were discarded during the washing steps. The homogeneity of erythrocyte suspensions was monitored by FACS analysis. After the buffy coat removal, the remaining nonerythroid cells (CD45-, CD16-, or CD36-positive cells) were Ͻ0.02% of the total cell population (supplemental Fig. S.1 ). Washed erythrocytes were subsequently resuspended to a hematocrit of about 10% and immediately used for further experiments. All studies were performed in the presence of 3 mM L-arginine (L-Arg) unless stated otherwise.
Epo Binding Studies
Binding of Epo to the mature murine erythrocytes was assessed by using 125 I-labeled recombinant human Epo ( 125 I-Epo) with a molecular mass of 34,000 Da and a specific activity of 30 TBq/mmol (Amersham Biosciences, Freiburg, Germany) as previously described (45) . Briefly, washed erythrocytes were resuspended at 5% hematocrit in incubation medium containing 0.1% BSA. Aliquots from the cell suspension (100 l) were incubated for 3 h at 4°C with different amounts of 125 I-Epo (24 -494 pM). Thereafter, nonbound radiolabeled Epo was removed by washing the cells three times with cold incubation medium, and cell-bound radioactivity was determined in a gamma counter (Kontron Gamma Counting System). Specific binding was determined by subtracting the values of 125 I-Epo in the presence of at least 100-fold excess of unlabeled recombinant human Epo (rHuEpo/Eprex, Janssen-Cilag, Baar/Schweiz) from those in the absence of nonlabeled rHuEpo. To investigate the nature of the Epobinding sites, we tested the maximal specific binding of iodinated Epo (240 pM 125 I-Epo, Ϯ excess of nonlabeled rHuEpo) in cells pretreated for 2 h with antibody (dilution 1:50) raised against EpoR (M-20, Santa Cruz Biotechnology, Heidelberg, Germany). Finally, to determine the distribution of Epo-binding sites within erythrocyte population, mouse RBCs were incubated with 240 pM 125 I-Epo for 2 h and were afterwards separated by density gradient centrifugation as described further. Cell-bound radioactivity from the separated cells was determined in a gamma counter or visualized autoradiographycally on an X-ray film.
Density Separation of Mouse RBCs
To divide mouse erythrocytes according to their age, RBCs were separated on continuous Percoll density gradient (Percoll Plus, GE Healthcare, Freiburg, Germany) as described previously (40) . The cells were divided into three fractions: reticulocytes and young RBCs (low cell density), adult (medium cell density), and old (high cell density) erythrocytes (supplemental Fig. S.2A ). The age of the different erythrocyte fractions was confirmed by the ratio of band 4.1a/4.1b as described elsewhere (5) (supplemental Fig. S.2 , B and C) The quality of the cell fractionation and the homogeneity of the RBC populations were verified by repeated density separation (supplemental Fig. S.3 ).
RBCs Treatment
Characterization of molecular mechanism and kinetics of Epo effect on the RBC-eNOS function. Erythrocytes from WT mice were incubated for 2 h at room temperature in the presence or absence of 1 U/ml rHuEpo. Aliquots were taken at 0, 30, 60, 120 min for Western blot analysis and for measurement of NO metabolites (NO 2 Ϫ /NO 3 Ϫ ) in the medium and cells. As a negative control, RBCs from eNOS Ϫ/Ϫ mice were subjected to the same experimental protocol and NO 2 Ϫ / NO 3 Ϫ levels in the medium, and cells were estimated. In additional experiments, erythrocytes from WT and eNOS Ϫ/Ϫ mice were incubated for 2 h in the presence or absence of L-Arg ,and the levels of nonprotein thiols were measured.
Dose response of Epo on the RBC-eNOS function. WT RBC were incubated with 0, 1, 10, 50, and 100 U/ml rHuEpo for 30 min at room temperature and RBC-eNOS activity was estimated. 
Erythrocyte Ghost Preparation
After treatment, erythrocytes were centrifuged at 4,000 g for 5 min at 4°C. Packed RBCs (about 500 l) were hemolyzed in 2 ml of ice-cold lysis buffer (10 mM Tris ⅐ HCl, 1 mM EDTA, 10 g/ml pepstatin A, 10 g/ml leupeptin, 5 g/ml aprotinin, 0.1 mM PMSF, 10 mM Na-pyrophosphate, and 10 mM NaF, pH 7.4). Membranes were pelleted at 47,000 g for 20 min at 4°C (Sorvall centrifuge RC-5B; rotor SS-34; Thermo Electron, Franklin, MA). The supernatant was used as cytosolic extract, and membranes were solubilized in lysis buffer containing 0.5% deoxycholate and 1% Triton X-100. The protein concentration of the samples was determined with BCA Protein Assay (Pierce; Rockford, IL) with BSA as a standard.
Western Blot Analysis
The proteins from both cytosolic and membrane fractions were separated by 7.5% or 10% SDS-PAGE (500 g protein/lane) and transferred to Protan BA83 nitrocellulose membranes (Schleicher and Schuell, Dassel, Germany). Protein transfer was controlled by Ponceau red staining. Membranes were blocked for 1 h at room temperature and incubated overnight at 4°C with primary antibodies against phospho-eNOS (Ser-1177; Cell Signaling Technology, Danvers, MA) or phospho-Akt/PKB␣ (Thr-308; Upstate, Lake Placid, NY). Staining with antibody against total actin was used as a loading control. After washing was completed, membranes were incubated for 1 h at room temperature with the corresponding horseradish peroxidase-conjugated secondary antibodies (anti-mouse/anti-rabbit; Jackson ImmunoResearch Laboratories, West Grove, PA). The enhanced chemiluminescence detection Western blotting system was used for signal visualization.
Evaluation of RBC-eNOS Activity
One of the widely used markers for NO production in biological systems are nitrite/nitrate (NO 2 Ϫ /NO 3 Ϫ ) levels because they are stable oxidation products of NO (32) . In our study, we measured NO 2 Ϫ in the incubation medium and RBCs using triiodide-based chemiluminescence assay described in detail elsewhere (19) . Briefly, an aliquot of 200 l from the RBC suspensions was taken at given times and centrifuged for 1.5 min at 13,200 g. One-hundred seventy microliters of the medium were immediately separated from the packed cells and placed on ice until the assay was performed. Erythrocytes were reconstituted with 70 l fresh, cold medium and lysed with 25 l of nitrite preservation solution containing 800 mM K 3Fe(CN)6, 100 mM N-ethylmaleimide, and 10% Nonidet-40. The samples were deproteinized by addition of 125 l methanol (100%) and centrifuged for 10 min at 13,200 g. Fifty microliters from the incubation medium or supernatant from the cell lysates were injected in the preheated (65°C) reaction chamber containing acidic triiodide (I 3 Ϫ ) reagent. The reagent was prepared fresh before the measurements by mixing 1.65 g KI, 0.57 g I 2, 15 ml ddH2O, and 200 ml glacial CH3COOH. The reaction chamber was purged with helium, and released NO was detected using CLD-88 analyzer (ECO MEDICS, Durnten, Switzerland). The signal was processed using PowerChrom 280 system (eDAQ Pty; Spechbach, Germany). To measure nitrate in the samples, we reduced the NO 3 Ϫ to NO 2 Ϫ using cadmium-copper-based reduction kit Nitralyzer-II (World Precision Instruments, Sarasota, FL). The assay was performed according to the manufacturer instructions. After the reduction, NO 2 Ϫ was measured as described above. NO 3 Ϫ levels were estimated by the subtraction of NO 2 Ϫ levels before the reduction from those obtained after the conversion of NO 3 Ϫ to NO 2 Ϫ .
Measurements of Nonprotein Thiols
The amount of reduced (GSH) and oxidized (GSSG) glutathione was assayed in erythrocytes as described previously (6) . Briefly, samples from RBC suspensions were mixed 1:10 with deproteinizing solution containing 1.67 g glacial metaphosphoric acid, 0.2 g Na 2EDTA, 30 g NaCl,and 100 ml ddH2O. After centrifugation, GSH concentration was determined in supernatants using 5,5Ј-dithiobis(2-nitrobenzoic acid) (Ellman's reagent). Optical density of the colored complex was measured photometrically at 412 nm. Simultaneously, aliquots from the same samples were incubated in the presence of glutathione reductase and NADPH for reduction of GSSG to GSH, and total glutathione levels (GSHϩGSSG) were determined. The half-cell reduction potential (E hc) was calculated according to Schafer and Buettner (52) .
Measurements of Superoxide Anion Production
To evaluate the influence of L-Arg deprivation and Epo on generation of superoxide anions (O 2
•Ϫ ) by erythrocytes, we used chemiluminescence Superoxide Anion Assay Kit (CS1000). Erythrocytes (5 ϫ 10 6 ) were incubated for 2 h in the presence or absence of L-Arg or in the presence of 1 U/ml rHuEpo without eNOS substrate in the medium. The assay was performed according to the producer's guideline.
Statistical Analysis
All data are based on at least six experiments and are presented as means Ϯ SE. The comparison between the experimental groups was performed using ANOVA and two-tailed Student's t-test for unpaired samples (GraphPad Instat.V3.05). The level of statistical significance was set at P Ͻ 0.05.
RESULTS

Epo Binding to Murine Erythrocytes
Treatment of WT mouse erythrocytes with 125 I-Epo in the presence and in the absence of excessive amounts of nonradioactive Epo revealed a specific binding of Epo to the RBC membranes (Fig. 1A) . The equilibrium binding isotherm (Fig. 1B ) and scatchard analysis (Fig. 1B, inset) indicated the presence of a single-type Epo-binding site with high affinity to Epo (K d ϭ 58.3 Ϯ 11.1 pmol/l). We further performed separation of mouse erythrocytes pretreated with 125 I-Epo according to their age. It is known that RBC density increases with cell aging (40) . Using Percoll density gradient, RBCs were divided into three major fractions: reticulocytes ϩ young RBCs (low density), adult erythrocytes (medium density), and old cells (high density), as shown in supplemental 105 Ϯ 8 for low-density, 4 Ϯ 1 for medium-density, and 2 Ϯ 1 for high-density RBCs. The results obtained by using the gamma counter were confirmed autoradiographycally. After the separation of mouse erythrocytes, pretreated with radioactive Epo, X-ray film was placed next to the centrifuge tube for about 6 h. A specific band at the level of low-density erythrocyte fraction was observed (Fig. 1D) . Unfortunately, no bands were detected on the film from the adult and old erythrocyte populations, most probably due to the weaker and diffuse signal.
For further characterization of the Epo binding sites in mouse erythrocytes, the cells were pretreated with an antibody against Epo-R (M-20, dilution 1:100). This resulted in a reduction of the specific 125 I-Epo binding from 427.5 Ϯ 77.6 to 47.11 Ϯ 136.1 dpm/100 l RBCs. Obtained results suggest that murine erythrocytes specifically bind Epo and that its binding sites are recognized by EpoR-specific antibodies.
In addition, Epo binding to mouse erythrocytes was visualized using biotinylated human Epo and concomitant staining with the avidin conjugated with fluorescein. Double-staining using antibodies against transferrin receptors allowed us to specifically assess interaction of Epo with reticulocytes. As shown in Fig. S.4 reticulocytes showed strong Epo-positive staining, whereas the Epo binding to mature erythrocytes was much weaker and could not be detected in all cells but in some. These data are in line with those obtained using 
Epo Triggers Activation of the Akt and eNOS Phosphorylation
We have further monitored the activity of the PI3K/Akt cascade known as a common EpoR-sensitive signaling pathway (21, 22, 28, 47) . The cells were incubated in the absence or presence of 1 U/ml rHuEpo for the period of 2 h, and aliquots of cell suspensions were collected after 30 min, 1 h and 2 h of treatment with the cytokine. Since Kleinbongard et al. (33) reported the presence of eNOS in both cytosolic and membrane fractions in human erythrocytes, we have used both cytosolic and membrane protein extracts for the assessment of Epo effect on the Akt and eNOS phosphorylation state. Western blot analysis revealed an increased phosphorylation of Akt in the cytosolic extracts from RBCs treated with 1 U/ml rHuEpo compared with the Epo-free controls (Fig. 2A) . The phosphorylation peaked in the cells exposed to Epo for 30 min and decreased thereafter. The activation of Akt was followed by an increase in the phosphorylation of eNOS, one of its downstream targets. As shown in Fig. 2B , exposure of RBCs to 1 U/ml rHuEpo caused phosphorylation of the RBC-eNOS at Ser-1177. Upregulation of Ser-1177 phosphorylation could be detected in the membrane fractions already 30 min after cytokine administration reaching its maximum within 1 h of Epo treatment. Phosphorylation of eNOS at Ser-1177 is known to activate the enzyme (43) . Therefore, we followed the kinetics and dose dependence of Epo action on the NO production in murine erythrocytes.
Kinetics of Epo effect on RBC-eNOS activity. We used NO 2 Ϫ /NO 3 Ϫ levels in the cells and incubation medium as markers of NO production (32) by erythrocytes treated with various doses of rHuEpo for various time periods. The exposure of mouse erythrocytes to 1 U/ml rHuEpo triggered upregulation of NO production. The rate of NO 2 Ϫ accumulation in the incubation medium was doubled in the presence of 1 U/ml rHuEpo ( Fig. 3A; 2.27 Ϯ 0.39 compared with 0.87 Ϯ 0.13 mol/h ⅐l cells in the Epo-free control). The intracellular NO 2 Ϫ levels in nontreated cells transiently decreased during the incubation, whereas Epo administration resulted in a slow accumulation of NO 2 Ϫ in the RBCs (Fig. 3B) . The NO 3 Ϫ cellular content in control erythrocytes was practically constant over 2 h of incubation but increased profoundly in the Epo-treated erythrocytes already after 30 min of incubation (Fig. 3D) . Our data suggest that most of de novo produced NO and resulting NO 2 Ϫ were either removed from the cells or rapidly oxidized to nitrate when in the cytosol. The resulting steady-state levels of NO 3 Ϫ in Epo-treated RBCs were threefold exceeding those in control cells (Fig. 3D) . Concomitantly, the rate of NO 3 Ϫ accumulation in the incubation medium was threefold higher in the presence of Epo ( Fig. 3C ; 179.9 Ϯ 25.5 compared with 63.04 Ϯ 18.1 mol/h ⅐l cells in the Epo-free control).
The obtained results suggest that treatment of mouse erythrocytes with 1 U/ml rHuEpo caused a threefold increase in the RBC-eNOS activity that could be detected already 30 min after the cytokine administration. Therefore, 30-min incubation period was chosen for the assessment of the dose response of Epo action on the eNOS function.
Dose Dependence of Epo Effect on RBC-eNOS Activity
The concentration of Epo (1 U/ml, rHuEpo) that we used when studying kinetics of Epo-induced RBC-eNOS activation reflects the endogenous cytokine plasma levels after physio- logical stimulation by hypoxia or decreased blood hemoglobin (1, 21, 28) . Therapeutic Epo doses used in the clinics however vary between 150 and 40,000 U/kg (21, 28, 47) . Thus Epo plasma levels in patients reach 10 -100 U/ml. To characterize the effects of physiological and therapeutic doses of Epo on the RBC-eNOS activity, we incubated WT erythrocytes with increasing amount of rHuEpo ranging between 1 and 100 U/ml.
Epo-induced changes of NO 2 Ϫ /NO 3 Ϫ levels in the erythrocytes and the medium over 30 min of incubation were dose dependent, with a peak at 10 U/ml rHuEpo (Fig. 4) . When higher Epo doses were applied (50 -100 U/ml), NO 2 Ϫ levels were somewhat lower than those at 10 U/ml. Of note, similar biphasic dose-dependent induction of NO production by Epo was reported in endothelial cell lines (4). (Fig. 5, A and C) . The intracellular NO 2 Ϫ /NO 3 Ϫ levels in eNOS Ϫ/Ϫ erythrocytes decreased with time (Fig. 5, B and D 
Lack of Epo Effect on NO
White Blood Cells Do Not Contribute to Epo-Induced Regulation of RBC-eNOS
In the next set of experiments we assessed the possible influence of white blood cell contamination of the erythrocytes suspension on Epo-induced NO production. Whole blood samples and buffy coat-free erythrocytes suspension were exposed to 10 U/ml Epo for 1 h and the NO 2 Ϫ /NO 3 Ϫ accumulation in the cells and the medium compared with those for the Epo-free samples. There was no difference in the rates of Epo-induced ⌬NO 2 Ϫ accumulation (⌬NO 2 Ϫ , 0.67 Ϯ 0.13 mol/h ⅐l RBC with and 0.69 Ϯ 0.18 mol/h ⅐l RBC without buffy coat) or in the Epo-induced intracellular NO 3 Ϫ accumulation (⌬NO 3 Ϫ , 387.6 Ϯ 86.5 mol/h ⅐l RBC with and 370 Ϯ 49.3 mol/h ⅐l RBC without buffy coat) between the whole blood and the buffy coat-free samples. Obtained results confirm the specific, direct, Fig. 3 and acute modulatory effect of Epo on the erythrocyte NO production.
Blocking of Epo-Induced Activation of RBC-eNOS
To further characterize the mechanism behind Epo-induced activation, we blocked different components of the putative signaling pathway and monitored the NO 2 Ϫ /NO 3 Ϫ levels in the presence or absence of Epo. NO production by Epo was completely abolished by the pretreatment of RBCs with 1 M PI3K inhibitor wortmannin, 150 M Akt blocker A6730 or EpoR antibody (M-20, dilution 1:100) (Fig. 6 ). In addition, the direct blocking of de novo NO production by pretreatment of the cells with L-NMMA, prevented Epo-induced increase of intra-and extracellular NO 2 Ϫ /NO 3 Ϫ levels (Fig. 6) . These results are in agreement with the data obtained for the Epo-induced phosphorylation of Akt and RBC-eNOS, suggesting that Epo regulates erythrocyte NO production via PI3K/Akt-mediated RBC-eNOS activation.
L-Arg Availability and Epo-Treatment Modulate the Redox State of RBCs
Under certain conditions, such as substrate deficiency, eNOS is capable of generation of superoxide anions (O 2
•Ϫ ) instead of NO (14, 44) , causing oxidative stress. We tested whether Epo may induce an oxidative stress in RBCs deprived of L-Arg. The effect of Epo on NO production and cellular redox state in RBCs incubated in L-Arg-containing and L-Arg-free medium was monitored. Epo failed to increase NO 2 Ϫ /NO 3 Ϫ levels in the erythrocytes and incubation medium in the absence of L-Arg (data not shown). Moreover, the omission of L-Arg triggered a •Ϫ generation by the RBCs, which was further facilitated by Epo (Fig. 7A) .
Both, NO and O 2 •Ϫ generation contribute substantially to the maintenance of the cellular redox state. We measured intracellular reduced (GSH) and oxidized (GSSG) glutathione levels after 2 h of incubation with 1-100 U/ml rHuEpo in the presence and absence of L-Arg and expressed the data as a half-cell redox potential for the GSH:GSSG couple (52) . Incubation of the RBCs in L-Arg-free medium shifted the halfcell reduction potential to more oxidized (Fig. 7B) . Treatment of the erythrocytes with 1 U/ml rHuEpo in absence of L-Arg further facilitated GSH oxidation (Fig. 7B) . In L-Arg-containing medium the redox potential was preserved in cells incubated with 1 U/ml rHuEpo for at least 2 h. Acute treatment of RBCs with a therapeutic dose of 100 U/ml rHuEpo in the presence of L-Arg caused a statistically significant decrease in the half-cell reduction potential, indicating a shift to more reduced state. Our data suggest that the influence of Epoinduced regulation of RBC-eNOS on the cellular redox state depends on the presence of L-Arg. Depending on the L-Arg availability, Epo may play a dual role as pro-or antioxidant.
Finally, we tested whether Epo and L-Arg will affect the cellular redox state of the eNOS Ϫ/Ϫ erythrocytes. As expected, the availability of the eNOS substrate was without an effect on the half-cell redox potential of eNOS-deficient RBCs (Ϫ291.7 Ϯ 5.6 mV in the presence and Ϫ290.2 Ϯ 3.3 mV in the absence of 3 mM L-Arg in the medium). Moreover, 100 U/ ml rHuEpo failed to affect the cellular redox state in the presence or absence of L-Arg (Ϫ287.6 Ϯ 13.4 in the absence and Ϫ292.4 Ϯ 8.5 in the presence of 3 mM L-Arg in the medium).
DISCUSSION
Our study is the first to characterize the interaction of Epo with murine RBCs. The obtained data imply that eNOS is one of the targets of Epo action in mouse erythrocytes. By activating RBC-eNOS, Epo may have a profound effect on a number of cellular properties of which maintenance of the redox potential is of key importance.
Characteristics of Epo Binding Sites on Murine Erythrocytes
We have detected the presence of Epo binding sites on murine erythrocyte membrane. Skatchard analysis of the data on the dose response of 125 I-Epo binding (Fig. 1B and inset ) reveals a single binding site class with a K d ϭ 58.3 Ϯ 11.1 pmol/l, a value within the range of affinity of classical EpoR to Epo reported in the literature (30 to 330 pmol/l) (9, 45, 54, 60) . The wide scatter of the K d values reveals a broad tissue-and species-specific variability of the EpoR properties. Interaction of Epo with the erythrocyte membrane could be abolished by pretreatment of the cells with an antibody against mouse EpoR, Ϫ levels in the medium of eNOS Ϫ/Ϫ erythrocytes were significantly lower compared with WT. Epo administration did not cause any change in the extracellular NO 2 Ϫ levels. B: Epo administration was without an effect on the intracellular NO 2 Ϫ content in eNOS Ϫ/Ϫ RBCs. C: basal NO 3 Ϫ levels in the incubation medium of eNOS Ϫ/Ϫ erythrocytes were lower compared with WT RBCs. Epo treatment did not alter the extracellular NO 3 Ϫ levels. D: addition of rHuEpo to eNOS Ϫ/Ϫ erythrocytes failed to affect cytosolic NO 3 Ϫ levels. *P Ͻ 0.05 WT control compared with eNOS Ϫ/Ϫ control, #P Ͻ 0.05 WT control compared with eNOS Ϫ/Ϫ RBCs treated with 10 U/ml rHuEpo; n ϭ 10; means Ϯ SE.
which was claimed to target the receptor specifically (20) . Furthermore, Epo binding to the cells activated PI3K/Akt signaling cascade (Figs. 2 and 6 ), a well-characterized downstream signaling pathway of a common EpoR in erythroid precursor cells (21, 22, 28, 47) . Taken together, these observations suggest that Epo interacts with a common Epo receptor present on erythrocyte membranes. The low number of receptors as well as the absence of reliable highly specific antibodies makes the direct molecular identification technically demanding.
Previous studies using 125 I-Epo to track Epo binding to human erythrocytes reported the presence of 5-6 Epo binding sites per cell, based on the assumption that the number of specific Epo binding sites is equal for each erythrocyte (45) . If the same assumption is applied to our data, similar numbers may be obtained (5-6 Epo binding sites per mouse erythrocyte). However, the number of binding sites per cell varies between 100 and 2 binding site per cell, being most abundant Fig. 7 . Effect of L-Arg deprivation and Epo on cellular redox state. A: superoxide anion (O2
•Ϫ ) production of WT RBCs was measured during 2 h of incubation period using luminescent assay in the presence or absence of 3 mM L-Arg. L-Arg deprivation resulted in pronounced increase of O2
•Ϫ generation. Administration of 1 U/ml rHuEpo in the absence eNOS substrate was accompanied by further increase in O2
•Ϫ production. B: WT erythrocytes were incubated for 2 h in the presence or absence of 3 mM L-Arg. At the beginning of the incubation, RBCs were separated in several groups and treated with either saline, 1 U/ml, or 100 U/ml rHuEpo. At the end of the incubation period, samples were taken for measuring of reduced and oxidized glutathione (GSH/ GSSG). Half-cell reduction potential (Ehc) was calculated as previously described (52) . eNOS substrate deprivation resulted in increased Ehc compared with the L-Arg-containing control thus shifting cellular redox state to more oxidized. Epo treatment led to further oxidation of GSH. In contrary, in the presence of L-Arg low Epo levels did not affect Ehc. Moreover, therapeutic doses of Epo (100 U/ml) exerted antioxidative effect by decreasing the Ehc and respectively altering redox potential of the RBCs to more reduced. *P Ͻ 0.05 compared with L-Arg containing control, #P Ͻ 0.05 compared with L-Argdeficient control; n ϭ 6; means Ϯ SE. in reticulocytes (Fig. 1, C and D; supplemental Fig. S.4) . The marked decrease in Epo-binding capability with cell aging is most likely achieved as Epo receptor is released in vesicles during cell maturation (39) or undergoes internalization and proteasomal degradation similar to transferrin receptor (25) . EpoR internalization with a following degradation or partial recycling was reported for erythroid precursor cells (24, 59) but never before in the circulating erythrocytes despite the presence of proteasomal machinery in mature RBCs (30) .
The results we obtained suggest that all erythrocytes have a potential to be Epo sensitive, but the degree and significance of the cellular response may be age dependent. Unfortunately, no functional studies can be performed on the Epo-induced NO production in subfractions obtained by Percoll density gradient centrifugation, since the contact with the Percoll rendered the cells Epo insensitive (data not shown). Since released, NO may diffuse affecting all the neighboring cells when in blood stream. Therefore, the Epo effects on NO production that we have observed in nonseparated RBCs population are physiologically relevant even when generated by relatively few cells.
Epo-Induced Regulation of Erythrocyte NO Production
We have shown that Epo triggers an increase in the activity of the eNOS in mouse erythrocytes by promoting phosphorylation of the enzyme at Ser-1177 by Akt (Fig. 2) . This adds Epo to the list of physiological regulators of the RBC-eNOS along with insulin, acting through the same signaling cascade (33) . RBC-born NO, in addition to the upregulation of NO production by endothelial cells and cardiac myocytes, would facilitate the cytoprotective effect of Epo (4, 12, 42, 51) .
Since Epo is strongly considered as a potential cardioprotective agent (7, 12, 22, 28) , the dose dependence of the NO release is of particular importance. The acute upregulation of NO production in RBCs could be detected after administration of 1 U/ml rHuEpo (Fig. 3) . This Epo concentration exceeds the one found in normoxic human or mouse blood (0.001 to 0.027 U/ml) (21, 28, 47) by several orders of magnitude but might be reached in vivo in response to hypoxia or anemia (1-10 U/ml) (1). We cannot exclude that the long-term effects of Epo on RBC-eNOS may be observed at much lower doses than those used in our study. Epo doses used in the clinics are however in the range between 150 and 40,000 U/kg corresponding to 10 -100 U/ml in plasma (21, 28, 47) . Our data indicate that the increase in Epo dose above 10 U/ml does not cause further increase in the NO production (Fig. 4) . In fact the Epo-induced regulation of RBC-eNOS was biphasic and resembled the dose response for Epo-induced NO generation reported in the endothelial cells (4) .
Role of Epo in Controlling the Cellular Redox State
eNOS is actively involved in the regulation of intracellular redox state. Under conditions of substrate or cofactor deficiency and in response to atherogenic stimuli, eNOS generates superoxide anions along or instead of NO (14, 44) . We have shown that this is the case when Epo-induced activation of RBC-eNOS occurs in L-Arg-free medium (Fig. 7) . The obtained results imply that Epo can be pro-or anti-oxidant depending on the conditions. Oxidative stress is one of the factors triggering RBCs senescence (37, 38 •Ϫ production may be reduced compared with that we report here. However, under pathological conditions, Epo-induced changes in cellular redox state may become significant.
Our results may have particularly important consequences for the pathophysiology of rHuEpo therapy. Increased oxidative stress is a feature characteristic in patients with chronic renal failure undergoing hemodialysis (HD) (27, 36, 48) . Several publications reported that Epo treatment of uremic patients on chronic HD is accompanied by further increase of oxidative stress and requires coapplication of antioxidants (17, 35, 46) . A possible cause for these observations could be L-Arg deficiency and uncoupling of eNOS activity via inhibition of L-Arg uptake (10, 41, 62) or changes in extracellular L-Arg content (10, 11, 61) . Our data suggest that coapplication of Epo and L-Arg would help to avoid probable side effects of Epo treatment. However, our observations were made for mouse erythrocytes and thus cannot be directly transferred to human RBCs. Further experiments are needed to assess the relevance of our findings for human erythrocytes.
Physiological Relevance of Epo-Induced Activation of the eNOS in RBCs
Our findings along with the previous reports raise an important question that remains to be answered: what is the role of RBC-born NO and Epo-induced regulation of RBC-eNOS activity? When Epo plasma levels increase under hypoxic conditions, together with an augment in RBC mass, Epoinduced NO production could improve tissue's blood supply due to NO-mediated vasodilatation (16, 31, 53) . The relative contribution of RBC-eNOS activity to the total NO pool remains to be characterized. The increase in RBC-derived NO would reduce the scavenging of NO produced by endothelial cells, thereby facilitating NO-induced vasodilatation. Under hypoxic conditions, the NO 2 Ϫ to NO conversion may be catalyzed by membrane-bound deoxyhemoglobin (16, 19, 31, 53) . Under O 2 saturating conditions, RBC-eNOS synthase will contribute most to the RBC-derived NO production. Apart of controlling vascular tone, RBC-derived NO pool serves the local needs; e.g., increasing membrane fluidity and RBC deformability (8, 33) thus improving capillary perfusion and reducing sheer stress (58) . Furthermore, oxygen release from hemoglobin in hypoxic conditions is also enhanced by NO as it reduces the oxygen affinity of hemoglobin, thus facilitating the oxygen transfer from erythrocytes to the tissues (34, 55) .
Another interesting aspect that draws attention is the unequal distribution of Epo binding sites within RBC population and its role for the cells. According to our findings reticulocytes and young erythrocytes contain much more Epo receptors compared with the adult and old ones, suggesting that young RBCs are more sensitive to changes in Epo plasma levels. Over the last years several papers appeared describing a process of selective lysis of relatively young erythrocytes called neocytolysis (2, 50, 57) . Neocytolysis occurs in individuals acclimatized to high altitude on descent to sea level or astronauts ascending into space and is considered as a physiological process for downregulation of excessive RBC mass (2). The exact mechanism of neocytolysis is still unclear, but it was found that it is accompanied by decrease of Epo plasma levels and selective removal of relatively young erythrocytes, generated over the previous 10 -11 days (49) . Our data suggest that the number of Epo-binding sites may be the key factor for selecting and survival of the different erythrocyte fractions. The greater number of Epo-binding sites on the young RBCs could explain their preferential removal when Epo plasma levels drop below a certain threshold.
In summary, our findings indicate that mouse erythrocytes possess classical EpoRs, the number of which per cell depends on the RBC age. Epo activates RBC-eNOS and regulates the distribution of NO-bioactive species between the RBCs and the medium. Furthermore, the Epo-induced regulation of eNOS activity affects redox state of the RBCs by generation of NO or O 2
•Ϫ depending on L-Arg bioavailability. Pro-oxidative potential of rHuEpo should be seriously considered when using this drug in clinics.
